Globenewswire·2026-01-12 14:00Core Viewpoint - Orchestra BioMed Holdings, Inc. is set to receive up to $21 million in cash proceeds from the acquisition of Vivasure by Haemonetics Corporation, which closed on January 9, 2026, highlighting the strategic value of Vivasure to Orchestra BioMed [1][2]. Group 1: Financial Expectations - Orchestra BioMed expects to receive $11 million in proceeds during 2026, consisting of approximately $5 million upfront and about $6 million as a first milestone payment, with the remainder to be earned based on future revenue milestones [2][5]. - The total expected proceeds from the acquisition amount to $21 million, indicating a significant financial benefit for Orchestra BioMed [1]. Group 2: Product and Technology Overview - Vivasure's PerQseal® Elite system utilizes a proprietary bioabsorbable patch for sealing large-bore arteriotomies and venotomies, providing a sutureless and fully absorbable solution for various medical procedures [3]. - The PerQseal Elite system has received CE Mark approval in Europe and a Premarket Approval application has been submitted to the U.S. FDA, showcasing its regulatory progress and market potential [3]. Group 3: Strategic Partnerships and Development - Orchestra BioMed has been a strategic partner of Vivasure since its inception, actively supporting the development of the PerQseal technology [3][4]. - The collaboration with Haemonetics is expected to enhance the commercial prospects of the PerQseal Elite system, leveraging Haemonetics' market presence in the large-bore closure market [3][7]. Group 4: Company Background - Orchestra BioMed is focused on accelerating high-impact biomedical technologies through strategic collaborations, with flagship products like AVIM Therapy and Virtue® Sirolimus AngioInfusion™ Balloon undergoing pivotal clinical trials [4][6]. - The company aims to address significant health issues, such as hypertension and atherosclerotic artery disease, which represent multi-billion-dollar market opportunities [4][6].